Introduction
With an estimated 1.6 million of people dying every year lung cancer remains a world-wide health problem 1 and is the second most common cancer in the UK. In 2014, over 40,000 new cases were diagnosed 2 . Histologically, 80% of lung cancer relate to non-small cell type 2 , which is incurable by cancer treatments at later stages.
Unfortunately, lung cancer is often diagnosed when the cancer is in its advanced stage; in 2008 it was estimated that three quarters of the newly diagnosed patients in England and Wales were diagnosed with a stage III or IV cancer. For NSCLC the one year and ten year survival rates for stage III disease are 35% and 6% respectively whilst for patients presenting with stage IV disease, the one-year survival rate is 14%, with a median survival of 6 -8 months 2 .
Although various targeted therapies have helped to increase survival rates for small subgroups of patients (e.g. EGFR and KRAS mutations; PD-L1 inhibitors), combination chemotherapies remain the dominant approach towards treatment for NSCLC 3 4 . For these patients, who cannot be offered curative treatments, the National Institute for Health and Clinical Excellence 5 guidelines highlight the potential benefit of palliative care and recommends that patients who may benefit from palliative care (drug and non-drug based) services should be referred without delay. 3 intervention aiming at improving patient participation in the consultations around treatment pathways will also lead to fairer access to healthcare 8 .
Shared-decision making has been identified as the pinnacle of patient-centred care 9 10 because it legitimizes the patient's right to make decisions about their care 11 . Crucial to this process is a commitment from both parties to exchange information 12 13 . Clinicians provide reliable evidence-based information on the likely benefits and harms of interventions or actions, including any uncertainties and risks whilst patients convey information about the effect of the illness on their lives, their values and preferences. Patient's knowledge and preferences are taken into account alongside the clinician's expertise.
The UK Government aims to place patients' needs, wishes and preferences at the heart of the clinical decision-making by making shared-decision making (SDM) the norm throughout the NHS 14 . However, SDM is far from being routinely implemented alongside the patient clinical care pathway 11 . Joseph-Williams and colleagues 15 reviewed patient-reported barriers and facilitators to SDM and identified two main themes: "how the health care system is organized" (time, continuity of care, workflow, and characteristics of the health care setting) and "what happens during the decision-making interaction" (patient characteristics, power imbalance in the patient-clinician relationship, preparation for a SDM encounter, and preparation for a SDM process). The authors conclude that patients need knowledge and feel empowered to participate in SDM and that any interventions aiming to improve SDM should take account of the relationships between these factors and focus on both sides.
Patients diagnosed with advanced non-small lung cancer (NSCLC) are having to live with a poor terminal prognosis. Treatment decisions made within the context of end of life care are undoubtedly complex, however, it cannot be assumed that restricted options should be presented, and these patients are too sick to be involved in SDM. Belanger and colleagues concluded that albeit a substantial minority prefers passive roles, the majority of terminally ill patients want to participate in their treatment decisions 16 . Unmet information needs, unrealistic expectations, the way options are framed, and delaying decisions constitute barriers to SDM. These factors echo and complement findings by Joseph-Williams and colleagues 15 . Patients with advanced, life-limiting cancer express a desire for full information, with two-thirds of patients wanting to actively participate in decision-making 17 .
For lung cancer patients, Lifford 18 found that SDM was not routinely implemented, patients' individual values were not elicited, and treatment decisions were not deliberated together 18 . Patients experience significant misunderstandings concerning the extent of disease, prognosis, and the aims of treatment, and there is evidence of an ongoing process of collusion concerning 'false optimism' communicated and shared by patients and their physicians 19 . Given the prior mediation of treatment management within MDT meetings, which take place after initial diagnosis, (figure 1), it is possible that patients are further disenfranchised from the decision-making process during the patient-clinician consultation stage, as they may not receive full disclosure of all available treatment options, including associated benefits and burdens, to help aid and inform their decision-making 17 20 .
The limitations of available treatments for lung cancer, balanced against the increasing and compelling evidence for a combined approach of oncology and palliative care, indicate the need to enable clinicians to introduce palliative care as an option at an early stage 5 21 .
However, timely referral to palliative care services might be complicated by patient's poor understanding of palliative care services and intentions 22 and clinicians' concern about removing hope 23 although evidence in fact suggests that the opposite is the case, with patients feeling more involved in decision-making when given the opportunity to speak about palliative care 24 25 .
The ability to discuss palliative care whilst managing its associated connotations is challenging, however, early palliative interventions can lead to less aggressive treatment, limit futile treatments, reduce symptom severity and problems associated with medical interactions whilst improving patients' quality of life, overall mood and satisfaction with care [26] [27] [28] In addition to this there is now a growing body of evidence to suggest that SACT for certain patients and cancer characteristics is likely to increase early treatment-related mortality [29] [30] [31] [32] [33] . Four of these studies were UK based and one included 9634 patients diagnosed with NSCLC 33 .
Patients want more information than their clinicians perceive they do 34 , and physicians poorly predict these preferences within the context of palliative care 34 35 . For all the above reasons, a clear understanding of the balance of risk and benefits of SACT treatment and other options, such as palliative care, and of patients' preferences are critical to promote shared and informed decision-making in the best interest of patients and prudent healthcare 36 .
Aims and objectives
The PACT study aims to identify the information and decision support needs of patients diagnosed with advanced NSCLC, and to develop an intervention to support those patients and their clinicians when considering treatment options, including SACT and/or referral to, or integration with, palliative care. The objectives are to:
1. Observe treatment decision-making for lung cancer patients and patient allocation to services during MDT interactions; 2. Observe communication of options and decision-making during doctor-patient consultations; 3. Explore patients' and clinicians' understanding and attitudes towards the delivery of treatment options for lung cancer and risk/benefits; 4. Develop and face-test an intervention to support patients and clinicians when considering treatment options. 
Methods

Study design
PACT is a prospective, multimethod and multicentre study. The data collection process is sequential, and has been designed to generate a rich understanding of the treatment decision-making process for NSCLC, starting from the beginning point of the MDT meeting and ending with the oncology appointment with the patient, following the patient pathway within the health care system (figure 1).
Figure 1: The lung cancer patient pathway
The methodology comprises five stages (figure 2). Stage one is a discrete event and will not influence participant selection in the later stages of the project. The data collected in stages 2-4 will be related to the same patient/doctor dyad.
Recruitment and sampling
Recruitment and data collection will take place in three National Health Services (NHS) respiratory oncologic clinics, set within three different Health Boards in Wales (see supplement material 1 
Observation of Lung Multi-Disciplinary Team Meeting (Stage one)
The aim is to study how treatment decisions are determined, and how patients are allocated to treatment pathways. Four lung MDT meetings will be observed for each health board. Consent for data collection will be negotiated via nominated chairpersons of the meeting. Information sheets and consent forms signed by all contributing members are required for an MDT meeting to be considered for data collection.
Direct non-participant observation will be employed 37 . Non-participant observation enables the recording of nonverbal communication, interactional behaviours and proxemics 38 39
. Audio-recording will minimise bias, securing the actual verbatim of participants interactions 37 40 . One or more researchers will observe the MDT. Researchers will be selected for their methodological experience, academic background and familiarity with the clinical environment. They will be seated away from observed communications and will keep initial field notes and manage the digital recorder. Field notes will specify date, time, location and study site (see supplement material 2). Observations regarding meeting membership, seating arrangements, equipment used, and time keeping will be made. Patient-specific observations will also be made, focusing on the presentation of the patient, any information provided and considered, the key contributors to discussion, the process of decision-making and the nature of negotiation or how this is managed. In-depth, descriptive and reflective notes recording the researcher's observations will be completed as soon as possible after each observed consultation 40 41 .
Thematic analysis and mediated discourse analysis will be used to analyse the MDT data. Thematic analysis 42 will identify the most appropriate segments of data for further exploration with mediated discourse analysis. Thematic analysis will follow Brown and Clarke's model and use five phases to establish meaningful patterns and issues of potential interest: a) familiarisation with the data; b) generating initial codes; c) searching for themes among codes; d) reviewing themes; and e) defining and naming themes 43 .
The MDT meetings are events with established memberships, customs and practices, which may differ across health boards. Mediated discourse analysis, a focus on discourse in action in communities of practice will be used to explore the interactions and discussions between MDT attendees, examining how treatment decisions are determined, and the communication patterns and decision-making processes of the MDT members 44 . Attention will be paid to the general dynamics of the meeting with a deeper analysis of critical or key moments of interactions, use of questions, agreement and disagreement.
Observation of patient-clinician consultation (Stage two)
Stage two aims to measure patient's involvement in decision-making and their perceptions of the discussion of treatment options. Clinicians who work with patients to discuss treatment options at each of the three sites are eligible to participate. The researcher will discuss the project with them and provide information sheets and consent forms. Clinicians who agree to participate will sign individual consent forms before approaching patients about PACT.
Patients and their companions (i.e. persons accompanying patients to consultation meetings) will be offered recruitment to the study in order that their communications may also be captured. Clinicians will identify eligible patients after their MDT allocation to oncology. Between 7 and 10 participants (and their respective clinicians) will be recruited from each health boards. Inclusion and exclusion criteria are listed in table 1. Clinicians will provide potential participants with information sheets and consent to contact in the form of a reply slip. If reply slips are returned the researcher(s) will contact the patient directly to discuss the study. Consent to participate will be taken by the observing researcher at the patient's next clinic appointment, and consultations will be observed.
Companions will be consented as well.
Patient-clinician consultations will be audio-recorded on digital recorders. The researcher will take consent before the consultation and will manage the digital recorder and write field notes during the consultation. Observations will focus on proxemics, nonverbal communication and interactional behaviours. If participants do not wish to consent to the researcher being present they will be given the option of our audio-recorded consultations. 46 . From the transcripts, the researcher will rate the clinician's level of expertise for 12 'patient-involving' behaviours on Likert-type scales ranging from 0 (no attempt to perform the behaviour) through to 4 (the behaviour is performed to a high standard); the sum of these scores are standardised to provide a score of 0-100 to indicate the "overall level of patient-involving competencies" of the clinician during the consultation. Individual item scores will also be used to identify areas where additional information and/or a different approach to the presentation of the information may be of benefit. To validate results, a second researcher will independently score the consultations.
Thematic analysis 42 will be used to explore in greater detail how treatment management options are presented to patients and their involvement in decision-making during their consultation with clinicians. Clinical members of the research team will assess any clinically orientated topics collected under the OPTION headings.
Semi-structured interviews with Patients (Stage three)
Stage three aims at capturing patients' experiences of their consultation in relation to perceptions of the available treatment options and their involvement in decision making.
Patients who participated in Stage two will be invited to face-to-face interviews. Information regarding interviews will be provided after observations. Interviews will take place within two to four weeks of the observed consultation. A second, interview-specific, round of consent will be taken from patients and companions (where present) by the researcher, prior to interview, allowing at least 24 hours to review the information sheet. Participants will be telephoned by the researcher to arrange a convenient date and time for the interview to take place.
Semi-structured interviewing will be the primary data collection method for this stage 47 .
This will provide space for patients to share and reflect on thoughts and feelings regarding consultation experiences whilst allowing researchers to specifically explore questions regarding patients' understanding of treatment options and their involvement in treatment decision-making (see supplement material 3). Questions are designed to mirror the OPTION instrument (see box 1), which will subsequently be used to inform data analysis. If a physical location proves inconvenient, interviews will be conducted by telephone, using call recording equipment. Interviews are expected to be approximately 30 -60 minutes in length, and may be terminated at any point if a patient participant indicates they wish to stop, if they are clearly fatigued or if they become unwell.
Interviews will be recorded and transcribed verbatim. Field notes made with participant's permission will record details of specific incidents occurring during the interview, and any non-verbal communication. The right of the participant to refuse to participate in the study without giving reasons will be respected. Similarly, the participant will remain free to withdraw at any time from the study. All data will be withdrawn at request.
In the event of participant distress due to discussion of sensitive topics, or if a clinical or work related issue emerges, the researchers, using their experience, will react at the time and will refer the issue to the participant's clinical team, with their permission.
A Framework Analysis 48 49 approach will be used to explore the pre-determined areas of interest informed by the OPTION instrument. Interpretative Phenomenological Analysis (IPA) will be also used to explore key emergent themes from the semi-structured interviews, focusing on how patients interpret their experience of the consultation process 50 . IPA aims to understand the meaning that events or states have for participants based on their subjective accounts. The transcript of each interview will be analysed sequentially, following four stages: a) preliminary reading; b) Initial comments are grouped into themes; c) Connections between themes is developed until an organised master list and thematic account of the case is achieved; d) Subsequent transcripts: New themes will be tested against the previous cases as non-recurring themes are tested against following cases.
Connections across cases will be noted to identify a set of super-ordinate themes for the group 50 .
Semi-structured interviews with Clinicians (Stages 4)
Stage four aims to explore clinicians' views on treatment management options for lung cancer patients, their experiences in presenting these options to patients, with a focus on risk/benefit, and their perceptions on how involved patients are in their treatment decisions. Similarly to phase 3, face-to-face semi-structured interviews will be used and questions will follow the OPTION instrument domains.
Clinicians participating in the observations of patient-clinician consultations will be interviewed across the three different health boards. Clinicians will be consented to the interview at the same time as they consent to the observation of their patient consultations. Signed consent from the clinicians will be taken by the researcher at the time of interview subject to the participant having at least 24 hours to review the information sheets.
The right of the clinician to refuse to participate in the study without giving reasons will be respected. Similarly, the clinician will remain free to withdraw at any time from the study and all data will be withdrawn at request.
Interviews will take place as soon as possible following the observations of clinician's respective consultations. Clinicians will be interviewed at the clinician's clinic or office In the event of clinician distress due to discussion of sensitive topics, or if a clinical or work related issue emerges, the researchers, using their experience, will react at the time and if needed, they will advise clinicians to contact the BMA Counselling Service 51 or they will refer the issue to the National Counselling Service for Sick Doctors, with the participants' permission 52 .
The interviews will be carried out by an experienced researcher under the remote supervision of a member of the research team. The researcher will digitally record the interview but may also make field notes (with the participant's permission) to record incidents occurring during the interview, non-verbal communication, or reactions at the time of the interview.
As with the patient interviews, IPA will be used to explore how clinicians make sense of their situations in their personal context according to individual experience, values and training 50 .
Intervention development (Stage five)
Phases I to IV will form an appropriate theoretical framework to guide the design, development and subsequent evaluation of the intervention 53 . Stage five aims to develop an intervention and face-test it for its usability with a representative patient group. An expert panel of stakeholders will be convened and consulted to refine the design, development and content of the intervention. Experts will be identified via a review of the most relevant literature in the field as well as clinical networks. Lay and professional stakeholders will be identified using Patient and Public Involvement (PPI) networks. Information sheets and consent forms will be distributed via e-mail. Signed consent will be taken before the meeting.
The stakeholders meeting will follow the nominal group technique (NGT) approach 54 . This structured group discussion ensures contribution from each participant whilst minimising researcher-bias. The expert consultation will help ensure that the appropriate evidence base is incorporated into the design of the intervention.
Group discussions will be recorded and transcribed verbatim. Field notes made with participant's permission will be made by the researcher(s). Thematic analysis 42 and ranking exercises will be used to summarise the data.
The intervention will be face tested for usability with a convenience sample of patients (n=10-15). Each participant will also be asked to take part in follow-up cognitive interviews 55 . Potential participants will be recruited via participating MDTs and given information about the study. The inclusion and exclusion criteria applied within stage two will apply. Participants will be telephoned by a researcher and a convenient time and place for interview will be arranged. Signed consent from participants will be taken at the time of interview by the researcher, allowing at least 24 hours to review the information sheets.
Cognitive interviews are conducted face-to-face. Participants will be asked to answer questions outlined within the intervention tool, with the aim of collecting information about the content, format and ease of understanding regarding the proposed intervention 56 . Both 'think aloud' and 'probe' cognitive interviews techniques will be applied 55 .
Scripted and spontaneous probing will be used, following Willis' 55 taxonomy of six categories: comprehension, paraphrasing, confidence judgement, recall, specific probes, and general probes. The 'scripted' approach ensures that important aspects of the intervention are addressed. Complementing this approach, 'spontaneous' probing allows for an element of flexibility, enabling the interviewer to encourage further exploration on items which appear to be problematic 55 57 . The interviewer will maintain an awareness of behavioural cues related to specific items or questions, noting for example any signs of discomfort or distraction.
Interviews will be recorded and transcribed verbatim and thematic analysis 42 will be used to analyse the transcripts. The intervention tool will be adjusted, if necessary, following analysis of this dataset.
Ethical considerations
The study follows the Research Governance Frameworks for England and Wales 58 59 and guidelines from the National Patient Safety Agency
60
. Ethical approval was granted (REC 14/WA/1103).
All participants will be able to withdraw at any point without impacting their medical care or relationship with their clinical team. Informed consent will be taken by the researcher collecting the data, who has undertaken Good Clinical Practice (research) training.
The PACT research team will preserve the confidentiality and anonymity of participants and handle all research data according to the principles of the Data Protection Act 61 . Transcribed recordings will be anonymised before analysis. Data will be stored on a password protected computer located in secure University buildings and appropriately backed up. Data transfer across participant organisations will be closely monitored and contractually agreed. All data will be retained for up to 15 years post study closure. Study documents will be retained for 15 years and then archived according to the MCPCRC policy. 64 , the PACT research team has recruited two lay, actively involved representatives. The lay representatives will contribute with ideas around recruitment of participants and ways to describe the study. The lay representatives will also contribute to interpret and contextualise the study findings. They will review selected transcripts and their comments will inform the data analysis and interpretation of findings. Additionally, the lay representatives will guide and contribute to the dissemination of the results to appropriate patient groups.
Dissemination
We hope that study findings will provide evidence for the development of national guidelines for care, which support both the regional Wales Government (WG) initiative of 'achieving prudent health care' 36 and the international initiative of 'choosing wisely', currently led by the Medical Royal College in the UK 65 and reduce 'overtreatment'. Specific dissemination strategies of the study findings will include: a) meetings with the clinicians involved into the study to ascertain how the study findings can enhance the MDT chart guidelines on best practice; b) a lay summary of the study findings will be produced and disseminated amongst key patient support groups; c) seminars will be given at departmental level; d) local, national and international conferences presentations will be made to disseminate both study methodology and findings; e) peer-reviewed publications will include papers on the main study results and papers attached to specific study stage and methodology; f) study newsletters will be regularly produced and disseminated to key stakeholders; g) Media and press releases via the Marie Curie Palliative Care Research Centre and centre Twitter and Facebook account. competency to actively engage in the consultation should they wish so. This means that any 80 intervention aiming at improving patient participation in the consultations around 81 treatment pathways will also lead to fairer access to healthcare 8 . 82 83 Shared-decision making has been identified as the pinnacle of patient-centred care 9 10 84 because it legitimizes the patient's right to make decisions about their care 11 . Crucial to this 85 process is a commitment from both parties to exchange information 12 13 . Clinicians provide 86 reliable evidence-based information on the likely benefits and harms of interventions or 87 actions, including any uncertainties and risks whilst patients convey information about the 88 effect of the illness on their lives, their values and preferences. Patient's knowledge, 89 preferences and priorities are taken into account alongside the clinician's expertise. 90
The UK Government aims to place patients' needs, wishes and preferences at the heart of 91 the clinical decision-making by making shared-decision making (SDM) the norm throughout 92 the NHS 14 . However, SDM is far from being routinely implemented alongside the patient 93 clinical care pathway 11 . Joseph-Williams and colleagues 15 reviewed patient-reported barriers 94 and facilitators to SDM and identified two main themes: "how the health care system is 95 organized" (time, continuity of care, workflow, and characteristics of the health care setting) 96 and "what happens during the decision-making interaction" (patient characteristics, power 97 imbalance in the patient-clinician relationship, preparation for a SDM encounter, and 98 preparation for a SDM process). The authors conclude that patients need knowledge and 99 feel empowered to participate in SDM and that any interventions aiming to improve SDM 100 should take account of the relationships between these factors and focus on both sides. 101
Patients diagnosed with advanced non-small lung cancer (NSCLC) are having to live with a 102 poor prognosis. Treatment decisions made within the context of end of life care are 103 undoubtedly complex, however, it cannot be assumed that restricted options should be 104 presented, and these patients are too sick to be involved in SDM. Belanger and colleagues 105 concluded that albeit a substantial minority prefers passive roles, the majority of terminally 106 ill patients want to participate in their treatment decisions 16 . Unmet information needs, 107 unrealistic expectations, the way options are framed, and delaying decisions constitute 108 barriers to SDM. These factors echo and complement findings by Joseph-Williams and 109 colleagues 15 . 19 . Given the prior mediation of treatment management within MDT meetings, 117 which take place after initial diagnosis, (figure 1), it is possible that patients are further 118 disenfranchised from the decision-making process during the patient-clinician consultation 119 stage, as they may not receive full disclosure of all available treatment options, including 120 associated benefits and burdens, to help aid and inform their decision-making 17 20 . Even 121 when physicians discuss options between different treatments, they find difficult to discuss 122 the option of no 'treatment', despite the advance stages of cancer disease 21 . 123
The limitations of available treatments for lung cancer, balanced against the increasing and 124 compelling evidence for a combined approach of oncology and palliative care, indicate the 125 need to enable clinicians to introduce palliative care as an option at an early stage 5 22 . 126
However, timely referral to palliative care services might be complicated by patient's poor 127 understanding of palliative care services and intentions 23 and clinicians' concern about 128 removing hope 24 although evidence in fact suggests that the opposite is the case, with 129 patients feeling more involved in decision-making when given the opportunity to speak 130 about palliative care 25 26 . 131
The ability to discuss palliative care whilst managing its associated connotations is 132 challenging, however, early palliative interventions can lead to less aggressive treatment, 133 limit futile treatments, reduce symptom severity and problems associated with medical 134 interactions whilst improving patients' quality of life, overall mood and satisfaction with 135 care 27-29 In addition to this there is now a growing body of evidence to suggest that SACT for 136 certain patients and cancer characteristics is likely to increase early treatment-related 137 mortality [30] [31] [32] [33] [34] . 
Methods
164
Study design
165
PACT is a prospective, multimethod and multicentre study. The data collection process is 166 sequential, and has been designed to generate a rich understanding of the treatment 167 decision-making process for NSCLC, starting from the beginning point of the MDT meeting 168 and ending with the oncology appointment with the patient, following the patient pathway 169 within the UK health care system (figure 1). 170 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The aim is to study how treatment decisions are determined, and how patients are allocated 208 to treatment pathways. Four lung MDT meetings will be observed for each health board. 209 Consent for data collection will be negotiated via nominated chairpersons of the meeting. 210
Information sheets and consent forms signed by all contributing members are required for 211
an MDT meeting to be considered for data collection. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Clinicians who work with patients to discuss treatment options at each of the three sites are 249 eligible to participate. The researcher will discuss the project with them and provide 250 information sheets and consent forms. Clinicians who agree to participate will sign 251 individual consent forms before approaching patients about PACT. 252 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The clinical team at each site will identify and introduce the study to eligible patients. These 262 prospective participants will be given an information sheet and a letter with a reply slip. 263
When the reply slip is returned, the researcher(s) will contact the participant to discuss the 264 study and, if willing, to arrange to meet prior to their consultation. Consent will be taken by 265 the observing researcher at their next clinic appointment. Where family members or 266 companions are present, consent will be also sought. The contribution of family 267 members/carers may represent a core component of the consultation and it is therefore 268 important to capture. If the patient does not wish to take part, then the consultation will 269 not be recorded and the patient/ family will not be recruited to the study. If a companion 270
does not consent to the study-in contrast to the patient wish-, then their verbatim will be 271 removed from the transcriptions and it will not be included in the analysis. In the case that 272 more than one consultation is needed for a decision to be made, the researchers will follow 273 the patient at their next appointment(s), and will record the subsequent consultations. 274 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 will manage the digital recorder and write field notes during the consultation. Observations 276 will focus on proxemics, nonverbal communication and interactional behaviours. If 277 participants do not wish to consent to the researcher being present they will be given the 278 option of our audio-recorded consultations. 279
Patient-clinician consultations will be measured using the Observing Patient Involvement in 280 Shared Decision Making (OPTION) instrument 46 version 3. OPTION is a validated process 281 outcome measure used to study the extent to which clinicians' involve patient in decision-282 making within clinical consultations. The instrument has been used with a range of 283 consultations 47 . From the transcripts, the researcher will rate the clinician's level of 284 expertise for 12 'patient-involving' behaviours on Likert-type scales ranging from 0 (no 285 attempt to perform the behaviour) through to 4 (the behaviour is performed to a high 286 standard); the sum of these scores are standardised to provide a score of 0-100 to indicate 287 the "overall level of patient-involving competencies" of the clinician during the consultation. 288
Individual item scores will also be used to identify areas where additional information 289 and/or a different approach to the presentation of the information may be of benefit. To 290 validate results, a second researcher will independently score the consultations. 291
Thematic analysis 43 will be used to explore in greater detail how treatment management 292 options are presented to patients and their involvement in decision-making during their 293 consultation with clinicians. Clinical members of the research team will assess any clinically 294 orientated topics collected under the OPTION headings. 295 296
Semi-structured interviews with Patients (Stage three) 297
Stage three aims at capturing patients' experiences of their consultation in relation to 298 perceptions of the available treatment options and their involvement in decision making. 299
Patients and their companions who participated in stage two will be invited to face-to-face 300 interviews. Information regarding interviews will be provided after observations. Signed 301 consent from patients and companions-where present-will be taken by the researcher 302 prior to the interview, subject to the participant having at least 24 hours to review the 303 information sheets. Participants will be telephoned by the researcher within a week after 304 their consultation to arrange a convenient date and time for the interview. Interviews will 305 take place within 2 weeks of the observed consultation wherever possible, and no later than 306 4 weeks. We would like to keep flexibility with the timeframe of two to four weeks, as some 307 patients might start chemotherapy immediately after their consultation, and therefore 308 might not feel well enough to be interviewed that proximately. Similarly, if patients become 309 too ill to participate after consultation, they will be withdrawn from the next stage of the 310 study. 311 Semi-structured interviewing will be the primary data collection method for this stage 48 . 312
This will provide space for patients to share and reflect on thoughts and feelings regarding 313 consultation experiences whilst allowing researchers to specifically explore questions 314 regarding patients' understanding of treatment options and their involvement in treatment 315 decision-making (see supplement material 3). Questions are designed to mirror the OPTION 316 instrument (see box 1), which will subsequently be used to inform data analysis. 317 318 319 1. The clinician draws attention to an identified problem as one that requires a decision-making process Identifying the problem 2. The clinician states that there is more than one way to deal with the identified problem ('equipoise') Explaining Equipoise 3. The clinician assesses patient's preferred approach to receiving information to assist decision making (e.g., discussion in consultations, read printed material, assess graphical data, use videotapes or other media) attention to decreased engagement and verbal probing to check on participants' fatigue will 330 be initiated by the researcher, whereas non-verbal communication will be missed. 331
The right of the participant to refuse to participate in the study without giving reasons will 332 be respected. Similarly, the participant will remain free to withdraw at any time from the 333 study. All data will be withdrawn at request. 334
In the event of participant distress due to discussion of sensitive topics, or if a clinical or 335 work related issue emerges, the researchers, using their experience, will react at the time 336
and will refer the issue to the participant's clinical team, with their permission. 337
A Framework Analysis 49 50 approach will be used to explore the pre-determined areas of 338 interest informed by the OPTION instrument. Interpretative Phenomenological Analysis 339 (IPA) will be also used to explore key emergent themes from the semi-structured interviews, 340 focusing on how patients interpret their experience of the consultation process 51 . IPA aims 341 to understand the meaning that events or states have for participants based on their 342 subjective accounts. The transcript of each interview will be analysed sequentially, following 343 four stages: a) preliminary reading; b) Initial comments are grouped into themes; c) 344
Connections between themes is developed until an organised master list and thematic 345 account of the case is achieved; d) Subsequent transcripts: New themes will be tested 346 against the previous cases as non-recurring themes are tested against following cases. 347
Connections across cases will be noted to identify a set of super-ordinate themes for the 348 group 51 . 349 350
Semi-structured interviews with Clinicians (Stages 4) 351
Stage four aims to explore clinicians' views on treatment management options for lung 352 cancer patients, their experiences in presenting these options to patients, with a focus on 353 risk/benefit, and their perceptions on how involved patients are in their treatment 354 decisions. Similarly to phase 3, face-to-face semi-structured interviews will be used and 355 questions will follow the OPTION instrument domains. 356 Signed consent from the clinicians will be taken by the researcher at the time of interview 360 subject to the participant having at least 24 hours to review the information sheets. 361
The right of the clinician to refuse to participate in the study without giving reasons will be 362 respected. Similarly, the clinician will remain free to withdraw at any time from the study 363 and all data will be withdrawn at request. 364
Interviews will take place as soon as possible following the observations of clinician's 365 respective consultations. Clinicians will be interviewed at the clinician's clinic or office 366 according to preference. If a face-to-face interview is not feasible, a telephone interview 367 may be offered instead. Interviews will be approximately 30-60 minutes in length. 368
In the event of clinician distress due to discussion of sensitive topics, or if a clinical or work 369 related issue emerges, the researchers, using their experience, will react at the time and if 370 needed, they will advise clinicians to contact the BMA Counselling Service 52 or they will 371 refer the issue to the National Counselling Service for Sick Doctors, with the participants' 372 permission 53 . 373
The interviews will be carried out by an experienced researcher under the remote 374 supervision of a member of the research team. The researcher will digitally record the 375 interview but may also make field notes (with the participant's permission) to record 376 incidents occurring during the interview, non-verbal communication, or reactions at the 377 time of the interview. 378
As with the patient interviews, IPA will be used to explore how clinicians make sense of their 379 situations in their personal context according to individual experience, values and training 51 The stakeholders meeting will follow the nominal group technique (NGT) approach 55 . This 395 structured group discussion ensures contribution from each participant whilst minimising 396 researcher-bias. The expert consultation will help ensure that the appropriate evidence base 397 is incorporated into the design of the intervention. 398
Group discussions will be recorded and transcribed verbatim. Field notes made with 399 participant's permission will be made by the researcher(s). Thematic analysis 43 and ranking 400 exercises will be used to summarise the data. 401
The consensus meeting will lead to a national Delphi survey of the same stakeholders to 402 prioritise items in relation to outcome measure, format and content of the proposed 403 intervention. 404
The proposed intervention will be then face tested for usability with a convenience sample 405 of patients (n=10-15). Each participant will also be asked to take part in follow-up cognitive 406 interviews 56 . Potential participants will be recruited via participating MDTs and given 407 information about the study. The inclusion and exclusion criteria applied within stage two 408 will apply. Participants will be telephoned by a researcher and a convenient time and place 409 for interview will be arranged. Signed consent from participants will be taken at the time of 410 interview by the researcher, allowing at least 24 hours to review the information sheets. 411
Cognitive interviews are conducted face-to-face. Participants will be asked to answer 412 questions outlined within the intervention tool, with the aim of collecting information about 413 the content, format and ease of understanding regarding the proposed intervention 57 . Both 414 'think aloud' and 'probe' cognitive interviews techniques will be applied 56 . 415 Scripted and spontaneous probing will be used, following Willis' 56 taxonomy of six 416 categories: comprehension, paraphrasing, confidence judgement, recall, specific probes, 417 and general probes. The 'scripted' approach ensures that important aspects of the 418 intervention are addressed. Complementing this approach, 'spontaneous' probing allows for 419 an element of flexibility, enabling the interviewer to encourage further exploration on items 420 which appear to be problematic 56 58 . The interviewer will maintain an awareness of 421 behavioural cues related to specific items or questions, noting for example any signs of 422 discomfort or distraction. 423
Interviews will be recorded and transcribed verbatim and thematic analysis 43 will be used to 424 analyse the transcripts. The intervention tool will be adjusted, if necessary, following 425 analysis of this dataset. 426
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